OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.
Metabolomics uncovers metabolic alterations in biological samples and provides an overall picture of human or animal health: The information on complex biochemical processes obtained is highly valuable in drug mechanism and toxicology studies, biomarker discovery and the optimization of biotechnological processes.
OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.
"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.
OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.
Information for Shareholders about the fusion of Metabolic Renal Disease, S.L.U. and One Way Liver, S.L, available on news section.